Q3 2025 Ultragenyx Pharmaceutical Inc Earnings Call Transcript
Key Points
- Ultragenyx Pharmaceutical Inc (RARE) reported consistent double-digit annual revenue growth from its four commercial products.
- The company secured $400 million in nondilutive capital from OMERS, strengthening its financial position.
- Ultragenyx is on track to deliver total revenue between $640 million and $670 million for the year, representing 14% to 20% growth.
- The company is advancing multiple late-stage clinical programs with transformative commercial potential, including UX 143 and GTX-102.
- Ultragenyx has a strong global commercial organization, successfully launching products and expanding patient access across various regions.
- The company reported a net loss of $180 million for the quarter, highlighting ongoing financial challenges.
- Operating expenses were high at $331 million, including significant R&D and prelaunch inventory costs.
- There is uncertainty around the timing of pivotal data readouts for key clinical programs, which could impact future growth.
- The royalty revenue from Crysvita was impacted by expected seasonality, affecting short-term financial performance.
- Ultragenyx faces potential competition in the Angelman syndrome market, which could impact future market share.
Good afternoon and welcome to the Ultragenyx third quarter 2025 financial results conference call.
(Operator Instructions) It is not my pleasure to turn the call to Joshua Higa, Vice President of Investor Relations.
Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; and Eric Crombez, Chief Medical Officer. I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially.
Please refer to the risk factors discussed in our latest SEC filings. I'll now turn the call over to Emil.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
